The effect of the antithyroid drug methimazole (MMI) on cytochrome P450/P450 reductase-dependent activation of the anti-cancer prodrug cyclophosphamide (CPA) was investigated in a rat model of P450 prodrug activation-based cancer gene therapy. MMI treatment decreased the expression of hepatic P450 reductase by ϳ75% but did not alter P450 reductase levels in a 9L gliosarcoma growing in vivo as a subcutaneous solid tumor. In a pharmacokinetic study, MMI treatment significantly decreased the peak plasma concentration of the active, P450-generated metabolite 4-hydroxy-CPA, from 84.1 to 57.8 M, and substantially prolonged its apparent half-life, from 25.4 to 54.3 minutes. The area under the plasma concentration ϫ time curve and clearance values for 4-hydroxy-CPA were largely unchanged, however, indicating that MMI decreases the rate but not the overall extent of hepatic CPA activation. MMI alleviated some of the systemic toxicities of CPA treatment, as judged by the moderation of CPA-induced body weight loss and hematuria. The impact of MMI on CPA antitumoral activity was evaluated in rats implanted with 9L tumors transduced with P450 reductase in combination with the CPA-activating P450 2B1, which confers the capacity for intratumoral prodrug activation and leads to markedly enhanced chemosensitivity. CPA given as a single, subtherapeutic dose of 75 mg/kg resulted in a 13.8 day growth delay, whereas CPA in combination with MMI increased the growth delay to 17.4 days. By contrast, a tumor growth delay of only 3.4 days was observed in animals bearing 9L wild-type tumors given the same drug combination. We conclude that the selective reduction of liver P450 reductase after MMI treatment decreases the rate of hepatic drug activation and the host toxicity of CPA without loss of the antitumoral effect, thus increasing the therapeutic index of CPA in a P450-based cancer gene therapy model, where CPA undergoes localized drug activation at its intratumoral site of action.
C yclophosphamide (CPA) is an alkylating agent used in the treatment of malignant tumors and for organ transplantation. 1, 2 CPA is a prodrug that is activated by cytochrome P450 enzymes to form 4-hydroxy-CPA (4-OH-CPA), which ultimately decomposes to yield phosphoramide mustard, the active DNA cross-linking metabolite. Liver tissue has a high content of P450 enzymes active toward CPA 3, 4 and is the major organ responsible for CPA activation. Activated CPA generated in the liver circulates through the blood and gains entry to tumor tissue to exert its therapeutic effects. However, activated CPA can also reach bone marrow and other sensitive organs and can cause leukopenia and other dose-limiting systemic toxicities. 2 One approach to limit the systemic toxicities of CPA involves the expression of CPA-activating P450 enzymes in situ within the target tumor. Intratumoral (i.t.) CPA activation can result in a high, localized concentration of active drug metabolite at its site of action, which may maximize therapeutic effects while at the same time minimizing the host toxicities associated with hepatic drug activation. Human tumor tissues generally express low endogenous levels of P450, 5, 6 including those P450 enzymes from the CYP2B, CYP2C, and CYP3A families that activate CPA and its isomer ifosfamide. 7 However, this problem can be addressed by implementing a prodrug activation-based cancer gene therapy strategy using cytochrome P450 genes. 8 -12 In prodrug activation-based cancer gene therapy, a prodrug-activating gene is introduced into the tumor target using viral or nonviral vectors. 13 In the case of prodrugs such as CPA and ifosfamide, which generate active metabolites that readily diffuse from cell to cell, drug treatment kills not only tumor cells transduced with the prodrug activation gene, but also nearby, nontransduced tumor cells via a bystander cytotoxic effect. 9, 14 This bystander effect greatly amplifies the cytotoxic response and helps circumvent the limitations associated with inefficient gene delivery. Rat CYP2B1 and its human homolog CYP2B6, both active catalysts of CPA activation, 3, 4, 7 have been used for cancer gene therapy in rodent and human tumor model studies and have been shown to be particularly effective in enhancing the antitumoral activity of CPA when combined with reduced nicotinamide-adenine dinucleotide phosphate (NADPH)-P450 reductase gene transfer 12, 15 (reviewed in Ref. 16 ). The present study explores ways to enhance the efficacy and selectivity of P450-based cancer gene therapy by limiting the activation of CPA by hepatic P450 enzymes without diminishing its activation in tumor cells in situ. Potentially, this strategy can help minimize the liver metabolism-dependent systemic toxicities associated with CPA treatment, thus allowing for use of higher drug dosages and enhanced therapeutic responses. One approach is to use small molecule inhibitors designed to selectively inhibit hepatic but not tumor-expressed P450 enzymes involved in CPA activation. A second approach, investigated in this report, is to selectively suppress hepatic NADPH-dependent P450 reductase, which is an obligatory and often rate-limiting component required for electron transfer associated with all microsomal P450 monooxygenase reactions. 17, 18 Suppression of hepatic P450 reductase activity and gene expression can be achieved by using methimazole (MMI), a potent antithyroid drug 19 that substantially reduces hepatic P450 reductase gene expression and, consequently, P450/P450 reductase-dependent drug metabolism. 20, 21 The effect of MMI on hepatic and i.t. P450 reductase activity is presently evaluated, as are MMI's effects on CPA pharmacokinetics and antitumoral activity, both in a conventional tumor model and in the context of a model for P450-based cancer gene therapy.
MATERIALS AND METHODS

Materials
CPA, MMI, and NADPH were purchased from Sigma (St. Louis, Mo). 4-hydroperoxy-CPA was a gift from Dr. J. Pohl (ASTA Pharma, Bielefeld, Germany). All other chemicals were obtained from Sigma or Aldrich (Milwaukee, Wis). Rat P450 2B1 cDNA and rat P450 reductase cDNA used to prepare the retrovirus employed in the generation of 9L gliosarcoma transduced with P450 2B1 and P450 reductase (9L/2B1-Red) cells (see below) were those used in our earlier studies 9, 15 and were obtained from Dr. Milton Adesnik (New York University, New York, NY) and Dr. Gregorio Gil (Medical College of Virginia, Richmond, Va), respectively.
Animals
Male Fischer 344 rats (6 -7 weeks of age, 140 -150 g) were purchased from Taconic (Germantown, NY) and maintained in the Laboratory for Animal Care Facility at Boston University for ϳ1 week before beginning experiments, with food and water ad libitum. Rats were used for pharmacokinetic studies of CPA metabolism and for tumor growth delay assays, as described below.
MMI treatment
MMI was administered via the drinking water at a concentration of 0.025% (wt/vol), which induces hypothyroidism and results in a cessation of body weight gain within ϳ7 days. 19, 22 Control rats received drinking water without MMI. At 1 week after beginning MMI treatment, rats were implanted with 9L tumor cells or used for pharmacokinetic studies as described below. Rats were maintained on MMI until the conclusion of each experiment. Body weights were monitored two to three times per week.
Pharmacokinetics
Rats were treated with MMI for 7 days, at which time a catheter was inserted into the right atrium via the right jugular vein as described elsewhere. 23, 24 MMI treatment was continued for the duration of the experiment. After recovery from surgery for 3 days, an intravenous bolus of CPA (100 mg/kg) was administered to the rats. Blood (500 L at each timepoint) was withdrawn from the catheter at different timepoints (t ϭ 0, 4, 10, 25, 40, 60, 90, 120, 180, and 270 minutes) after CPA injection. For the t ϭ 0 minute timepoint, blood was withdrawn just before the injection of CPA to establish background metabolite levels and for calibration after spiking with standard 4-hydroperoxy-CPA. At each timepoint, the volume of blood withdrawn was replaced with an equal volume of sterile 0.9% saline. Blood samples containing CPA metabolites were mixed with 2 U of heparin and stabilized with 5 mM semicarbazide. Blood samples were centrifuged at 14,000 rpm for 4 minutes. Plasma samples (100 L) were transferred to new tubes and immediately frozen and stored at Ϫ80°C. Plasma samples were defrosted and derivatized for analysis by the fluorescence assay for CPA 4-hydroxylation, as described below.
Preparation and characterization of 9L/2B1-Red tumor cells
Rat 9L gliosarcoma is an in vitro-in vivo tumor model that is readily grown both in cell culture and as a subcutaneous (s.c.) solid tumor in vivo in Fischer 344 rats. 25, 26 9L is a useful tumor model for P450-based cancer gene therapy studies because of its deficiency in endogenous cytochrome P450. Three different 9L tumor cell lines were used in the present study: wild-type (9L/wt), 25 9L/pBabe, and 9L/2B1-Red. 9L/pBabe cells were prepared from 9L/wt cells by infection with the retroviral vector pBabe, as described previously.
12 9L/2B1-Red cells were obtained by sequentially infecting 9L/wt cells with retroviral vectors encoding rat P450 2B1 and rat NADPH-dependent P450 reductase. The general procedures used for construction of these retroviral vectors, the production of replicationdefective retroviral particles in Bosc 23 cells, 27 and the use of these particles for infection of 9L cells were carried out using methods detailed elsewhere. 12, 28 Briefly, a P450 reductasecontaining retroviral expression vector was constructed by ligating the EcoRI-XhoI fragment of full-length rat P450 reductase cDNA into an EcoRI-SalI-digested pBabe-based vector coding for hygromycin resistance. A P450 2B1-containing retroviral expression vector was constructed by ligating the EcoRI fragment of full-length P450 2B1 cDNA into the EcoRI restriction site of a pBabe-based vector coding for puromycin resistance. The orientation of the insert for each construct was verified by restriction digestion and DNA sequencing. Bosc 23 cells (ϳ80% confluent) were grown in 60-mm dishes and transfected with 8 g of pBabe-reductase-hygromycin or pBabe-2B1-puromycin by calcium phosphate precipitation. Retroviral supernatants harvested between 24 and 48 hours posttransfection were used to infect rat 9L gliosarcoma cells for 48 hours as described previously. 28 Cells were then split and selected with either hygromycin (300 g/mL for 3 days) or puromycin (2 g/mL for 2 days), as dictated by the drug resistance gene of the retrovirus. Characterization of the final pool of 9L/2B1-Red cells obtained using these methods revealed a 3.4-fold increase in microsomal P450 reductase activity (increase from 30 Ϯ 2 (9L/wt) to 101 Ϯ 6 nmol cytochrome c reduced/minute/mg protein at 30°C (9L/2B1-Red)) and an ϳ8-fold increase in microsomal P450 2B1-dependent 7-benzoxylresorufin O-dealkylation 29 measured at 4 M substrate (increase from 52 Ϯ 11 (9L/wt) to 422 Ϯ 20 pmol/minute/mg (9L/2B1-Red)) compared with 9L/wt cells. In addition, the expression of P450 2B1 protein and the overexpression of P450 reductase protein in microsomes prepared from 9L/2B1-Red cells was verified by Western blot analysis (data not shown).
Evaluation of effects of MMI on microsomal enzyme activities
Rats were treated with MMI for 7 days and subsequently implanted with 9L/wt cells at two s.c. sites per rat (2 ϫ 10 6 cells injected into each outer thigh). Tumor sizes were measured twice a week using Vernier calipers and expressed as areas (length ϫ width) according to Tomayko and Reynolds. 30 The rats were killed ϳ2 weeks later, when the tumors reached ϳ100 mm 2 in size. Microsomes were prepared by ultracentrifugation from liver, lung, kidney, and tumor tissue obtained from each rat for determination of microsomal P450 reductase and CPA 4-hydroxylase activities. Microsomal protein concentrations were assayed by the Bradford method using bovine serum albumin as the standard. NADPH-dependent P450 reductase activity was assayed by the reduction of cytochrome c, monitored at 550 nm.
20 CPA 4-hydroxylase activity was determined as described previously 4 in incubations containing 50 mM tris(hydroxy)aminomethane)/HCl buffer (pH 7.4), 15 mM MgCl 2 , 1 mM NADPH, 100 g of rat liver microsomal protein, and 0.25 mM CPA in a total volume of 0.1 mL. Reactions were incubated at 37°C for 60 minutes and subsequently deproteinized by the sequential addition of ZnSO 4, barium hydroxide, and HCl, as detailed below. Samples were then derivatized and assayed using the fluorescence assay for CPA 4-hydroxylation (see below).
Fluorecent assay for activated CPA
Plasma samples from pharmacokinetic studies (100 L) or from microsomal CPA 4-hydroxylation assays (100 L) were deproteinized by the sequential addition of 40 L of ice-cold 5.5% ZnSO 4 , 40 L of saturated barium hydroxide, and 40 L of 0.01 M HCl. Samples were spun at 14,000 rpm for 20 minutes. A portion of the supernatant (125 L) was transferred to a new tube and a mixture of 67 L containing 6 mg/mL 3-aminophenol and 6 mg/mL hydroxylamine hydrochloride (both dissolved in 1 N HCl) was then added. Samples were heated at 90°C for 30 minutes in the dark to convert acrolein (derived from 4-OH-CPA) to the fluorescent derivative 7-hydroxyquinoline. Samples were cooled to room temperature, and fluorescent intensities (excitation wavelength of 350 nm and emission wavelength of 515 nm) were measured using a Shimadzu RF-1501 spectrofluorophotometer (Shimadzu, Columbia, Md). Calibration curves were generated in parallel using 4-hydroperoxy-CPA (0 -10 nmol) and bovine serum albumin processed under the same assay conditions.
Tumor growth delay assay
Two independent experiments were carried out with a similar design but different doses of CPA and different 9L tumor cell lines. Each experiment used four groups of five rats each: (a) control group; (b) MMI treatment; (c) CPA treatment; and (d) combined MMI plus CPA treatment. Rats were treated with or without MMI for the duration of each experiment. At 7 days after the initiation of MMI treatment, 9L tumor cells were implanted by injection at two s.c. sites per rat (2 ϫ 10 6 cells/site). After 15-16 days, when the sizes of tumors reached ϳ100 mm 2 , the rats were given a single dose of CPA or 0.9% saline as a vehicle control by intraperitoneal (i.p.) injection. Tumor growth was monitored twice a week. For experiment 1, the dose of CPA was 100 mg/kg body weight (i.p.) and the tumor cells implanted were 9L/2B1-Red cells (left thigh) and 9L/pBabe cells (right thigh). For experiment 2, CPA was administered at 75 mg/kg body weight (i.p.) and the tumor cells implanted were 9L/2B1-Red cells (left thigh) and 9L/wt cells (right thigh). Tumor growth delay data were analyzed as described previously. 31 Tumor-doubling time was defined as the time in days required for the tumor to double in surface area. Tumor growth delay values were then calculated as the difference in tumor-doubling time between the drug-treated and control groups. Specific growth delay values were calculated as (T 2 Ϫ T 1 )/T 1 , where T 1 and T 2 are the times in days required for the control and the drug-treated tumors, respectively, to double in surface area. The specific growth delay parameter provides an estimate of the number of doubling times by which tumor growth is delayed by drug treatment, and provides for comparisons of therapeutic responses between tumors that differ in their growth rates. 31 
Data analysis
Data were organized with Microsoft Excel software and the graphic software package GraphPad Prism (GraphPad Software, San Diego, Calif). Pharmacokinetic parameters (area under the plasma concentration ϫ time curve (AUC), clearance, peak plasma concentration (C max ), and half-life (t 1/2 ) were calculated using WinNonlin software (Scientific Consulting, Cary, NC). Statistical analyses were performed using the unpaired two-tailed Student's t test with Microsoft Excel software.
RESULTS
MMI treatment significantly decreases P450 reductase protein and activity in rat liver and in some, but not all, extrahepatic tissues. 21 Experiments were carried out to determine the effects of MMI on P450 reductase activity in rats implanted with 9L gliosarcoma to ascertain whether the presence of the implanted tumor alters the inhibitory effect of MMI on liver P450 reductase reported earlier. In rats implanted with 9L/wt tumors, MMI treatment resulted in a ϳ75% decrease in liver P450 reductase activity (Fig 1A) . Hepatic microsomal CPA 4-hydroxylase activity in these livers decreased proportionally (Fig 1B) . MMI also reduced kidney P450 reductase activity by ϳ60%, but did not have any effect on lung P450 reductase (Fig 2) , in agreement with studies in non-tumor bearing rats. 21 MMI also did not decrease the endogenous level of P450 reductase activity in 9L tumors growing in the same animals (Fig 2) . The differential suppressive effect of MMI on the liver compared with tumor P450 reductase indicates that the thyroid hormone dependence of hepatic P450 reductase described earlier 20, 21 does not characterize the endogenously expressed 9L tumor P450 reductase gene, and suggests that MMI may be used to inhibit the P450/P450 reductase-dependent activation of CPA in the liver without blocking its in situ activation within these tumors.
To further confirm in vivo the effect of MMI on CPA metabolism suggested by the microsomal CPA 4-hydroxylation assays shown in Figure 1 , a pharmacokinetic study was carried out in rats treated with MMI (Fig 3) . MMI had only a modest effect on the AUC and clearance values for the activated metabolite 4-OH-CPA. However, C max values were substantially decreased, from 84.1 to 57.8 M, and the t 1/2 of 4-OH-CPA correspondingly increased from 25.4 to 54.3 minutes (Fig 3) , consistent with the decreased rate of hepatic CPA 4-hydroxylation seen in in vitro microsomal assays (Fig 1) .
The effect of MMI treatment on CPA antitumoral activity was examined using an in vivo tumor growth delay assay. 9L tumor cells expressing P450 2B1 and P450 reductase (9L/2B1-Red cells) were prepared by retroviral transduction and were characterized with respect to P450 2B1 and P450 reductase activity and expression as described in Materials and Methods. 9L/ 2B1-Red cells were implanted on the left thigh, and control tumors transduced with an empty retroviral vector (9L/pBabe) were implanted on the right thigh of each rat. The CPA antitumoral activity observed in tumors that express P450 2B1 and P450 reductase is a reflection of i.t. CPA activation plus hepatic CPA activation, whereas the activity seen in 9L/pBabe or 9L/wt tumors reflects hepatic activation of the prodrug alone. 15 Tumors were grown to ϳ100 mm 2 , at which point a single dose of CPA (100 mg/kg i.p.) was administered to the rats (experiment 1). MMI treatment slowed the growth of both 9L/2B1-Red and 9L/pBabe tumors by ϳ4 The rats used in this experiment were implanted with 9L/wt tumors growing s.c. Rats were treated with MMI at 0.025% (wt/vol) in drinking water for a total of 27 days, after which the animals were killed and liver microsomes were prepared. Microsomal P450 reductase and CPA 4-hydroxylase activities were assayed as described in Materials and Methods. Error bars represent mean Ϯ SD values for three rats per group. days (Fig 4) . CPA treatment delayed the growth of 9L/pBabe tumor by ϳ8 days compared with a 22-day growth delay for 9L/2B1-Red tumors (growth delay values determined at the point at which the tumors increased in size by 200 mm 2 ). This latter result confirms our earlier finding that the introduction of a CPAactivating CYP2B gene in combination with P450 reductase significantly enhances the antitumoral activity of CPA. 12, 15 However, MMI treatment did not further improve the antitumoral activity of the 100 mg/kg CPA treatment in 9L/2B1-Red tumors (Fig 4) , which may already be near-maximally inhibitory in this animal model.
In a separate series of experiments (experiment 2), 9L/wt cells were implanted as the control tumor and the dose of CPA was reduced from 100 mg/kg to 75 mg/kg. The antitumoral activity of CPA given alone or in combination with MMI was evaluated (Fig 5 and Table  1 ). As seen in experiment 1 (Fig 4) , CPA treatment alone had a significantly greater effect on 9L/2B1-Red tumors (13.8-day growth delay) than on 9L/wt tumors (5-day growth delay). Interestingly, the combination of CPA with MMI resulted in an enhanced tumor growth delay effect with the 9L/2B1-Red tumors (growth delay of 17.4 days) but not for the 9L/wt tumors (growth delay of 3.4 days). Overall, MMI increased the differential growth delay between 9L/wt and 9L/2B1-Red tumors in CPA-treated rats, from 13.8 -5 ϭ 8.8 days in the absence of MMI to 17.4 -3.4 ϭ 14 days in its presence. These values translated into a specific growth delay (i.e., the number of tumor area doubling times by which tumor growth is delayed) of 2.18 for 9L/2B1-Red tumors compared with only 0.77 for 9L/wt tumors in animals given CPA in combination with MMI ( Table 1) .
The systemic toxicities of CPA were evaluated by monitoring body weight changes after drug treatment Figure 3 . Plasma 4-OH-CPA concentrations in rats treated with MMI. Rats were treated with MMI for 1 week, at which point the rats had ceased to grow. A 4-OH-CPA pharmacokinetic study was then carried out as described in Materials and Methods. A single dose of CPA (100 mg/kg, intravenous bolus) was given to untreated rats or to MMI-treated rats, as indicated (n ϭ 5 rats/group). Plasma 4-OH-CPA concentrations were determined at each timepoint. Inset: Pharmacokinetic parameters determined using WinNonlin software. An asterisk represents the P value from the Student's t test (unpaired, two-tailed Student's t test) between control and MMI treatment. ‫,ء‬ P Ͻ .05; ‫,ءء‬ P Ͻ .01; ‫,ءءء‬ P Ͻ .001. ( Fig 6) . MMI-induced hypothyroidism fully blocked body weight gain in the absence of CPA treatment ( Fig  6A) . A single dose of CPA (100 mg/kg), administered on day 23 after the initiation of MMI treatment, caused a 15-to 20-g (6 -8%) body weight loss in euthyroid rats over the 7-day period after CPA administration, in agreement with our earlier studies. 32 This CPA-induced weight loss was prevented in MMI-treated rats (Fig 6B) , which although of lighter baseline weight than the controls that did not receive MMI, nevertheless remained quite healthy after CPA administration. CPA treatment also resulted in blood in urine in three of five rats in the group that did not receive MMI. This hematuria, a known toxicity of CPA, 33 was not seen in the MMI plus CPA group (data not shown). Thus, MMI ameliorates the host toxicities associated with CPA treatment without a loss of antitumoral activity.
DISCUSSION
The expression of P450 reductase in the liver and in certain extrahepatic tissues is thyroid hormone-dependent. 21 Three imperfect direct repeats of the thyroid response motif AGGTCA have been identified within the promoter region of P450 reductase 34 and may contribute to the large (Ն10-fold) increase in hepatic P450 reductase mRNA expression seen in hypothyroid rats after thyroid hormone treatment. 21 MMI treatment depletes circulating thyroid hormone and leads to a 75-85% loss of liver P450 reductase activity and protein, and to a less extensive decrease (30 -50%) in P450 reductase expression in the kidney, adrenal, lung, and heart. 21 Corresponding decreases in hepatic and kidney P450 reductase were seen in tumor-bearing rats in the present study. Hepatic microsomal CPA 4-hydroxylase activity was also decreased substantially in MMI-treated rats, a finding that is consistent with P450 reductase being a rate-limiting component for hepatic microsomal P450 activities. 17, 18, 20 In contrast to the effects of MMI on liver P450 reductase, MMI did not alter P450 reductase levels in the 9L gliosarcoma tumor model used in the present study, enabling us to evaluate the impact of this selective reduction of hepatic P450 reductase activity on CPA pharmacokinetics and CPA antitumoral activity in the context of an i.t. P450 expression model for cancer gene therapy. 16 In addition to the decrease in P450 reductase, MMI can also modulate the expression of several thyroid hormone-regulated liver cytochrome P450 enzymes, including CYP2A1, 35 CYP2C11, 36 CYP2E1, 37 CYP3A2,
36
CYP4A2, 38 -40 and CYP8B1. 41 Hypothyroidism associated with MMI treatment increases rat hepatic CYP3A2 protein and mRNA up to ϳ2-fold but decreases CYP2C11 activity and mRNA by 70 -80%.
36 CYP3A2 and CYP2C11 both contribute to microsomal CPA metabolism in uninduced rat livers: CYP3A2 primarily catalyzes CPA N-dechloroethylation, which inactivates the drug and forms the neurotoxic byproduct chloroacetaldehyde, 42 whereas CYP2C11 is a major catalyst of CPA activation via 4-hydroxylation. 3 Consequently, the decrease in the rate of hepatic microsomal CPA 4-hy- Figure 5 . Antitumoral effects of CPA and MMI evaluated at 75 mg/kg CPA (experiment 2). Tumor implantation, drug treatments, and data presentation are similar to those described in Figure 4 , except that a lower dose of CPA was used (75 mg/kg i.p., injected on day 0) and 9L/wt cells were used in place of 9L/pBabe tumor cells. CPA was administered on day 15 after tumor implantation, at which point the tumors were ϳ125 mm 2 in size (9L/wt) or ϳ70 mm 2 in size (9L/2B1-Red). The data shown are based on Figure 5 (experiment 2). Tumor doubling time, tumor growth delay, and specific growth delay were calculated as described in Materials and Methods. An asterisk indicates a tumor-doubling time that is statistically different from the control group: *, P Ͻ .01; **, P Ͻ .001. droxylation seen in hypothyroid (MMI-treated) rats (Fig  1) is likely to reflect the loss of both CYP2C11 and P450 reductase, the two major liver enzymes required for CPA activation in uninduced rat liver. The MMI-induced decrease in hepatic microsomal CPA 4-hydroxylase activity seen in our studies was associated with corresponding changes in CPA pharmacokinetics, as indicated by the decrease in C max and the increase in t 1/2 for 4-OH-CPA after MMI treatment (Fig 3) . Of note, however, the total amount of CPA that is ultimately converted to the active, 4-OH-CPA metabolite is not decreased in the MMI-treated rats, as evidenced by AUC values (Fig 3) . Consequently, MMI treatment does not compromise the antitumoral activity of CPA in the case of the wt tumors (Figs 4B and 5A, Table 1 ).
In contrast to these effects of MMI on hepatic CPA activation, several factors indicate that MMI treatment does not decrease the rate of CPA activation in situ in tumors transduced with P450 2B1 and P450 reductase. First, the endogenous P450 reductase gene of the 9L tumor is unresponsive to the inhibitory effects of thyroid hormone depletion (Fig 2) . Second, i.t. expression of P450 2B1 and the exogenous P450 reductase gene in 9L/2B1-Red tumors is regulated by the retroviral long terminal repeat, which is not known to be subject to thyroid hormone regulation, although thyroid hormone regulation has been described in the case of some lentiviruses. 43 The selective inhibition of hepatic drug activation in MMI-treated rats translated into an increase in the antitumoral effect of CPA beyond that seen for MMI treatment alone. CPA treatment significantly delayed the growth of 9L/2B1-Red tumors (a 13.8-day delay in tumor-doubling time compared with a 5-day delay in 9L/wt tumors) ( Table 1) . Whereas MMI treatment alone did not appreciably change the doubling time for 9L/wt or 9L/2B1-Red tumors, MMI increased the CPA-dependent growth delay of 9L/2B1-Red tumors somewhat, to 17.4 days. These findings highlight the potential benefit of using MMI or other antithyroid drugs that suppress hepatic P450 reductase 44 to enhance i.t. drug activation in the context of P450-based cancer gene therapy. Presumably, this increased activity results from a decrease in the rate of CPA activation in the liver, but not in the tumor in MMI-treated rats. This, in turn, may lead to a greater fraction of circulating CPA being activated i.t., thereby increasing the activity of CPA toward the P450-expressing tumor cells while sparing systemic host toxicity. Further investigation will be necessary to test this hypothesis and to evaluate other approaches aimed at increasing the fraction of the drug that undergoes P450-catalyzed activation within the tumor, compared with activation within the liver.
The inhibition of hepatic CPA activation in MMItreated rats was accompanied by a moderation of several systemic toxicities associated with CPA treatment. CPAinduced body weight loss and hematuria were not observed in the MMI-treated rats. This latter finding is consistent with an earlier report showing protection of rats given the antithyroid drug propylthiouracil from CPA-induced hemorrhagic cystitis, an effect that is suggested to result from a reduction in urinary excretion of acrolein, derived from CPA, in the hypothyroid animals. 33 Taken together, the improved anti-cancer effect and the lower systemic toxicities of CPA toward tumor cells transduced with P450/P450 reductase in rats treated with MMI clearly suggest that MMI, and perhaps other Figure 6 . Body weight changes in tumor-bearing rats as a function of CPA and MMI treatment. The body weight data shown correspond to the rats used in the tumor growth delay study (experiment 1) shown in Figure 4 . The large increases in weight seen in the non-MMI-treated groups primarily reflect the substantial increase in tumor mass during the time periods shown. MMI treatment began 23 days before CPA (i.e., 7 days before tumor implantation) and was effective in halting body weight gain within 7 days.
antithyroid drugs such as propylthiouracil, which also suppresses hepatic P450 reductase, 44 may have beneficial effects in P450-based cancer gene therapy. In addition, beneficial effects of MMI treatment itself were also apparent (e.g., Fig 5B) , in agreement with findings reported in several other tumor model systems. [45] [46] [47] For example, MMI is reported to protect against the nephrotoxicity induced by cisplatin. 48, 49 Moreover, a positive correlation between hypothyroidism and responses to drug treatment and longevity has been observed in patients with advanced solid tumors. 50 In one clinical case, a metastatic non-small cell lung cancer went into spontaneous remission after the patient suffered a myxedema coma, a life-threatening clinical state secondary to severe thyroid hormone deficiency. 51 The metabolic or molecular basis for these desirable effects of thyroid hormone depletion on tumor growth is unknown, but these effects can be seen both in cultured tumor cells 52 and in transplanted tumors growing in rat strains with differences in circulating thyroid hormone levels. 53 In conclusion, MMI both enhanced the anti-cancer efficacy of CPA in a P450-based cancer gene therapy model and alleviated some of the systemic toxicities associated with CPA treatment. The mechanism underlying these effects and the associated improvement in the therapeutic index have not been fully established, but are suggested to result from the decrease in the rate of hepatic CPA activation coupled with some intrinsic beneficial effects associated with the hypothyroidism induced by MMI treatment. Additional contributing factors could include the known free radical scavenger activity of MMI and perhaps its modulation of the immune system of the host. 54, 55 
